AtaiBeckley entered into a definitive merger agreement for its acquisition by Eli Lilly, offering $6.75 per share in cash plus a contingent value right of up to $2.50 per share based on clinical and regulatory milestones. The deal will be executed via a merger of Lilly subsidiary Albali Acquisition with AtaiBeckley, which will become a wholly owned subsidiary of Lilly. To support approval, Lilly also secured voting and support agreements from key AtaiBeckley stockholders, including directors, officers, and Apeiron Investment Group. Closing remains subject to stockholder approval, regulatory clearances, and other customary conditions.
Agreement 1: AtaiBeckley to Be Acquired by Eli Lilly for $6.75 Cash Plus Up to $2.50 CVR
- Agreement type: Agreement and Plan of Merger
- Counterparty: Eli Lilly and Albali Acquisition
- Signed / Effective: Jul 15 2026 / Jul 15 2026
- Duration / Termination: Until closing or termination
- Reason: Sell company to Eli Lilly with cash and CVR consideration
Agreement 2: Key AtaiBeckley Holders Sign Voting Agreements Supporting Eli Lilly Merger
- Agreement type: Voting and Support Agreements
- Counterparty: Certain stockholders including directors, officers and Apeiron Investment Group
- Signed / Effective: Jul 15 2026 / Jul 15 2026
- Duration / Termination: Until closing or termination of merger agreement
- Reason: Secure stockholder support for the merger
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.